Reunion to Participate in the ‘New Treatment Options Panel’ Discussion at the 2025 Maternal Mental Health FORUM on March 18 at 2:30 p.m. ET
Patient Enrollment Ongoing in Reunion’s Phase 2, 35 Site RECONNECT Study in Postpartum Depression (PPD)
MORRISTOWN, N.J., March 04, 2025 (GLOBE NEWSWIRE) — Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the advancement of next-generation psychedelic-inspired therapeutic solutions, today announced its participation in The Policy Center for Maternal Mental Health’s 2025 Maternal Mental Health (MMH) FORUM, taking place March 18-19, 2025.
“We are honored to participate in this forum as a featured panel presenter. Our partnership with the Policy Center for Maternal Mental Health reflects our belief in the importance of improving awareness of maternal mental health disorders – which impact up to 1 in 5 expecting and postpartum mothers in the United States – and in ensuring screening, diagnosis and treatment is standardized across the health delivery system,” said Greg Mayes, President and Chief Executive Officer of Reunion Neuroscience. “The MMH FORUM provides a much-needed venue for policymakers, payors and provider leaders to discuss solutions for closing the gaps in maternal mental health care, and we look forward to presenting on RE104 and our ongoing RECONNECT Phase 2 trial, as we work to deliver a potentially new approach to treating postpartum depression, which may offer mothers safe, fast-acting and effective relief.”
The RECONNECT Phase 2 clinical trial (NCT06342310), a multicenter, randomized, double-blind, active …
